These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 34229656)

  • 41. Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor.
    Bright JM; Carlisle HJ; Toda AMA; Murphy M; Molitor TP; Wren P; Andruska KM; Liu E; Barlow C
    Mov Disord; 2021 Jun; 36(6):1362-1371. PubMed ID: 33836114
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Parkinson's disease-related Leucine-rich repeat kinase 2 modulates nuclear morphology and genomic stability in striatal projection neurons during aging.
    Chen X; Xie C; Tian W; Sun L; Zheng W; Hawes S; Chang L; Kung J; Ding J; Chen S; Le W; Cai H
    Mol Neurodegener; 2020 Feb; 15(1):12. PubMed ID: 32075681
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of Targets from LRRK2 Rescue Phenotypes.
    Toh J; Chua LL; Ho P; Sandanaraj E; Tang C; Wang H; Tan EK
    Cells; 2021 Jan; 10(1):. PubMed ID: 33466414
    [TBL] [Abstract][Full Text] [Related]  

  • 44. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation.
    Zhao Y; Keshiya S; Perera G; Schramko L; Halliday GM; Dzamko N
    Neurobiol Dis; 2020 Oct; 144():105049. PubMed ID: 32800998
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development of a physiologically relevant and easily scalable LUHMES cell-based model of G2019S LRRK2-driven Parkinson's disease.
    Calamini B; Geyer N; Huss-Braun N; Bernhardt A; Harsany V; Rival P; Cindhuchao M; Hoffmann D; Gratzer S
    Dis Model Mech; 2021 Jun; 14(6):. PubMed ID: 34114604
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls.
    Gunzler SA; Riley DE; Chen SG; Tatsuoka CM; Johnson WM; Mieyal JJ; Walter EM; Whitney CM; Feng IJ; Owusu-Dapaah H; Mittal SO; Wilson-Delfosse AL
    J Neurol Sci; 2018 May; 388():203-207. PubMed ID: 29627023
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phosphorylation of amyloid precursor protein by mutant LRRK2 promotes AICD activity and neurotoxicity in Parkinson's disease.
    Chen ZC; Zhang W; Chua LL; Chai C; Li R; Lin L; Cao Z; Angeles DC; Stanton LW; Peng JH; Zhou ZD; Lim KL; Zeng L; Tan EK
    Sci Signal; 2017 Jul; 10(488):. PubMed ID: 28720718
    [TBL] [Abstract][Full Text] [Related]  

  • 48. G2019S-LRRK2 mutation enhances MPTP-linked Parkinsonism in mice.
    Arbez N; He X; Huang Y; Ren M; Liang Y; Nucifora FC; Wang X; Pei Z; Tessarolo L; Smith WW; Ross CA
    Hum Mol Genet; 2020 Mar; 29(4):580-590. PubMed ID: 31813996
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mitochondrial Calcium Dysregulation Contributes to Dendrite Degeneration Mediated by PD/LBD-Associated LRRK2 Mutants.
    Verma M; Callio J; Otero PA; Sekler I; Wills ZP; Chu CT
    J Neurosci; 2017 Nov; 37(46):11151-11165. PubMed ID: 29038245
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study.
    Mestre TA; Pont-Sunyer C; Kausar F; Visanji NP; Ghate T; Connolly BS; Gasca-Salas C; Kern DS; Jain J; Slow EJ; Faust-Socher A; Kasten M; Wadia PM; Zadikoff C; Kumar P; de Bie RM; Thomsen T; Lang AE; Schüle B; Klein C; Tolosa E; Marras C
    Mov Disord; 2018 Jul; 33(6):960-965. PubMed ID: 29665080
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Non-cell autonomous mechanism of Parkinson's disease pathology caused by G2019S LRRK2 mutation in Ashkenazi Jewish patient: Single cell analysis.
    Kim J; Daadi MM
    Brain Res; 2019 Nov; 1722():146342. PubMed ID: 31330122
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Investigation of microglial diversity in a LRRK2 G2019S mouse model of Parkinson's disease.
    Iovino L; VanderZwaag J; Kaur G; Khakpour M; Giusti V; Donadon M; Chiavegato A; Tenorio-Lopes L; Greggio E; Tremblay ME; Civiero L
    Neurobiol Dis; 2024 Jun; 195():106481. PubMed ID: 38527708
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The C-terminal domain of LRRK2 with the G2019S mutation is sufficient to produce neurodegeneration of dopaminergic neurons in vivo.
    Cresto N; Gaillard MC; Gardier C; Gubinelli F; Diguet E; Bellet D; Legroux L; Mitja J; Auregan G; Guillermier M; Josephine C; Jan C; Dufour N; Joliot A; Hantraye P; Bonvento G; Déglon N; Bemelmans AP; Cambon K; Liot G; Brouillet E
    Neurobiol Dis; 2020 Feb; 134():104614. PubMed ID: 31605779
    [TBL] [Abstract][Full Text] [Related]  

  • 54. LRRK2 mutation alters behavioral, synaptic, and nonsynaptic adaptations to acute social stress.
    Guevara CA; Matikainen-Ankney BA; Kezunovic N; LeClair K; Conway AP; Menard C; Flanigan ME; Pfau M; Russo SJ; Benson DL; Huntley GW
    J Neurophysiol; 2020 Jun; 123(6):2382-2389. PubMed ID: 32374202
    [TBL] [Abstract][Full Text] [Related]  

  • 55. RAB12-LRRK2 complex suppresses primary ciliogenesis and regulates centrosome homeostasis in astrocytes.
    Li X; Zhu H; Huang BT; Li X; Kim H; Tan H; Zhang Y; Choi I; Peng J; Xu P; Sun J; Yue Z
    Nat Commun; 2024 Sep; 15(1):8434. PubMed ID: 39343966
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Parkinson's-disease-associated mutation LRRK2-G2019S alters dopaminergic differentiation dynamics via NR2F1.
    Walter J; Bolognin S; Poovathingal SK; Magni S; Gérard D; Antony PMA; Nickels SL; Salamanca L; Berger E; Smits LM; Grzyb K; Perfeito R; Hoel F; Qing X; Ohnmacht J; Bertacchi M; Jarazo J; Ignac T; Monzel AS; Gonzalez-Cano L; Krüger R; Sauter T; Studer M; de Almeida LP; Tronstad KJ; Sinkkonen L; Skupin A; Schwamborn JC
    Cell Rep; 2021 Oct; 37(3):109864. PubMed ID: 34686322
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative blood transcriptome analysis in idiopathic and LRRK2 G2019S-associated Parkinson's disease.
    Infante J; Prieto C; Sierra M; Sánchez-Juan P; González-Aramburu I; Sánchez-Quintana C; Berciano J; Combarros O; Sainz J
    Neurobiol Aging; 2016 Feb; 38():214.e1-214.e5. PubMed ID: 26675812
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers.
    Dzamko N; Rowe DB; Halliday GM
    Mov Disord; 2016 Jun; 31(6):889-97. PubMed ID: 26917005
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synphilin-1 attenuates mutant LRRK2-induced neurodegeneration in Parkinson's disease models.
    Liu J; Li T; Thomas JM; Pei Z; Jiang H; Engelender S; Ross CA; Smith WW
    Hum Mol Genet; 2016 Feb; 25(4):672-80. PubMed ID: 26744328
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease.
    Marras C; Alcalay RN; Caspell-Garcia C; Coffey C; Chan P; Duda JE; Facheris MF; Fernández-Santiago R; Ruíz-Martínez J; Mestre T; Saunders-Pullman R; Pont-Sunyer C; Tolosa E; Waro B;
    Mov Disord; 2016 Aug; 31(8):1192-202. PubMed ID: 27091104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.